Tue . 20 Jul 2020
TR | RU | UK | KK | BE |

Neurofibromatosis type II

neurofibromatosis type ii, neurofibromatosis type ii mri
Neurofibromatosis type II also known as MISME syndrome - multiple inherited schwannomas, meningiomas, and ependymomas is a genetic condition which may be inherited or may arise spontaneously The main manifestation of the condition is the development of symmetric, benign brain tumors in the region of the cranial nerve VIII, which is the "auditory-vestibular nerve" that transmits sensory information from the inner ear to the brain Many people with this condition also experience visual problems NF II is caused by mutations of the "Merlin" gene,1 which seems to influence the form and movement of cells The principal treatments consist of neurosurgical removal of the tumors and surgical treatment of the eye lesions Historically the underlying disorder has not had any therapy due to the cell function caused by the genetic mutation However, new drug research and some clinical trials have shown some promise in having beneficial effects Collaborative research to find better treatments is ongoing, such as the work of the Synodos NF-2 Consortium of scientists


  • 1 Cause
  • 2 Pathogenesis
    • 21 Pathology
    • 22 Genotype-phenotype-correlation
  • 3 Diagnosis
    • 31 Prenatal
    • 32 Postnatal
  • 4 Treatment
    • 41 Surgery
    • 42 Systemic medical treatment
    • 43 Hearing loss
  • 5 Prognosis
  • 6 See also
  • 7 References
  • 8 Further reading


NF-2 may be inherited in an autosomal dominant fashion, as well as through random mutation

NF II is a microdeletion syndrome involving mutations in the NF2 gene located at 22q122 of chromosome 222 It is an inheritable disorder with an autosomal dominant mode of transmission Incidence of the condition is about 1 in 60,0003 There is a broad clinical spectrum known, but all patients checked have been found to have some mutation of the same gene on chromosome 22 Through statistics, it is suspected that one-half of cases are inherited, and one-half are the result of new, de novo mutations


NF II is caused by a defect in the gene that normally gives rise to a product called Merlin or Schwannomin, located on chromosome 22 band q11-131 This peptide is thought to have a tumor-suppressive function In a normal cell, the concentrations of active dephosphorylated merlin are controlled by processes such as cell adhesion which would indicate the need to restrain cell division It is known that Merlin's deficiency can result in unmediated progression through the cell cycle due to the lack of contact-mediated tumour suppression, sufficient to result in the tumors characteristic of Neurofibromatosis type II Mutations of NF II is presumed to result in either a failure to synthesize Merlin or the production of a defective peptide that lacks the normal tumor-suppressive effect The Schwannomin-peptide consists of 595 amino acids Comparison of Schwannomin with other proteins shows similarities to proteins that connect the cytoskeleton to the cell membrane Mutations in the Schwannomin-gene are thought to alter the movement and shape of affected cells with loss of contact inhibition Ependymomas are tumors arising from the ependyma, an epithelium-like tissue of the central nervous system In patients with NF2 and ependymomas, the tumor suppressant function of Merlin may be compromised Loss of function mutations occurring in chromosome 22q, where Merlin proteins are coded, can promote tumorigenesis, or the creation of new tumorous cells4 Deletions, too, in the NH2-terminal domain of merlin proteins have been associated with early tumor onset and poor prognosis in affected patients4


Schwannoma of the N Vestibularis Meningeomas in a person with NFII

The so-called acoustic neuroma of NF II is in fact a schwannoma of the nervus vestibularis, or vestibular schwannoma The misnomer of acoustic neuroma is still often used The vestibular schwannomas grow slowly at the inner entrance of the internal auditory meatus meatus acousticus internus They derive from the nerve sheaths of the upper part of the nervus vestibularis in the region between the central and peripheral myelin Obersteiner-Redlich-Zone within the area of the porus acousticus, 1 cm from the brainstem


Many people with NF II were included in studies that were designed to compare disease type and progression with exact determination of the associated mutation The goal of such comparisons of genotype and phenotype is to determine whether specific mutations cause respective combinations of symptoms This would be extremely valuable for the prediction of disease progression and the planning of therapy starting at a young age The results of such studies are the following:

  • In most cases the mutation in the NF II gene causes shortened peptides
  • There are no mutational hot-spots
  • Patients with frameshift mutations or nonsense mutations suffer poor prognosis
  • Patients with missense mutations have a better prognosis
  • In cases with mutations in the splice-acceptor-region, there is no good correlation to determine
  • Point mutations may have only minor effects
  • Cases are publishedcitation needed in which exactly the same mutation is associated with clearly different outcome

These results suggest that other factors environment, other mutations will probably determine the clinical outcome


NF-2 Locus


Bilateral vestibular schwannomas are diagnostic of NF25

NF II can be diagnosed with 65% accuracy prenatally with chorionic villus sampling or amniocentesis6


Ferner et al7 give three sets of diagnostic criteria for NF2:

  1. Bilateral vestibular schwannoma VS or family history of NF2 plus Unilateral VS or any two of: meningioma, glioma, neurofibroma, schwannoma, posterior subcapsular lenticular opacities
  2. Unilateral VS plus any two of meningioma, glioma, neurofibroma, schwannoma, posterior subcapsular lenticular opacities
  3. Two or more meningioma plus unilateral VS or any two of glioma, schwannoma and cataract

Another set of diagnostic criteria is the following:

  • Detection of bilateral acoustic neuroma by imaging-procedures
  • First degree relative with NF II and the occurrence of neurofibroma, meningiomas, glioma, or Schwannoma
  • First degree relative with NF II and the occurrence of juvenile posterior subcapsular cataract

The criteria have varied over time8


Early diagnosis allows better planning of therapy in young patients with NF II In many cases, the hearing loss is present for 10 years before the correct diagnosis is established Early in the condition, surgery for an acoustic neurinoma can protect facial nerve function in many patients In selected cases of patients with very small tumors and good bilateral hearing, surgery may offer the possibility of long-term hearing preservation

Patients with the Wishard phenotype suffer multiple recurrences of the tumour after surgical treatment In the case of facial nerve palsy, the muscles of the eyelids can lose their mobility, leading to conjunctivitis and corneal injury "Lidloading" implantation of small magnets, gold weights, or springs in the lid can help prevent these complications Other means of preserving corneal health include tarsorrhaphy, where the eyelids are partially sewn together to narrow the opening of the eye, or the use of punctal plugs, which block the duct that drains tears from the conjunctival sac All these techniques conserve moisture from the lacrymal glands, which lubricates the cornea and prevents injury Most patients with NF II develop cataracts, which often require replacement of the lens Children of affected parents should have a specialist examination every year to detect developing tumors Learning of sign language is one means of preparation for those that will most probably suffer complete hearing loss


There are several different surgical techniques for the removal of acoustic neuroma9 The choice of approach is determined by size of the tumour, hearing capability, and general clinical condition of the patient

  • The retrosigmoid approach offers some opportunity for the retention of hearing
  • The translabyrinthine approach will sacrifice hearing on that side, but will usually spare the facial nerve Post-operative cerebrospinal fluid leaks are more common
  • The middle fossa approach is preferred for small tumours, and offers the highest probability of retention of hearing and vestibular function
  • Less invasive endoscopic techniques have been done outside of the United States for some time Recovery times are reported to be faster However, this technique is not yet mainstream among surgeons in the US

Larger tumors can be treated by either the translabyrinthine approach or the retrosigmoid approach, depending upon the experience of the surgical team With large tumors, the chance of hearing preservation is small with any approach When hearing is already poor, the translabyrinthine approach may be used for even small tumors Small, lateralized tumours in patients with good hearing should have the middle fossa approach When the location of the tumour is more medial a retrosigmoid approach may be better

Auditory canal decompression is another surgical technique that can prolong usable hearing when a vestibular schwannoma has grown too large to remove without damage to the cochlear nerve In the IAC internal auditory canal decompression, a middle fossa approach is employed to expose the bony roof of the IAC without any attempt to remove the tumor The bone overlying the acoustic nerve is removed, allowing the tumour to expand upward into the middle cranial fossa In this way, pressure on the cochlear nerve is relieved, reducing the risk of further hearing loss from direct compression or obstruction of vascular supply to the nerve

Radiosurgery is a conservative alternative to cranial base or other intracranial surgery With conformal radiosurgical techniques, therapeutic radiation focused on the tumour, sparing exposure to surrounding normal tissues Although radiosurgery can seldom completely destroy a tumor, it can often arrest its growth or reduce its size While radiation is less immediately damaging than conventional surgery, it incurs a higher risk of subsequent malignant change in the irradiated tissues, and this risk in higher in NF2 than in sporadic non-NF2 lesions

Systemic medical treatmentedit

A 2009 clinical trial at Massachusetts General Hospital used the cancer drug Bevacizumab commercial name: Avastin to treat 10 patients with neurofibromatosis type II The result was published in The New England Journal of Medicine Of the ten patients treated with bevacizumab, tumours shrank in 9 of them, with the median best response rate of 26% Hearing improved in some of the patients, but improvements were not strongly correlated with tumour shrinkage Bevacizumab works by cutting the blood supply to the tumours and thus depriving them of their growth vector Side effects during the study included alanine aminotransferase, proteinuria, and hypertension elevated blood pressure among others10 A separate trial, published in The Neuro-oncology Journal, show 40% tumour reduction in the two patients with NF2, along with significant hearing improvement11

Overall the researchers believed that bevacizumab showed clinically significant effects on NF-2 patients However, more research is needed before the full effects of bevacizumab can be established in NF-2 patients

Hearing lossedit

Because hearing loss in those with NF-2 almost always occurs after acquisition of verbal language skills, patients do not always integrate well into the Deaf culture and are more likely to resort to auditory assistive technology The most sophisticated of these devices is the cochlear implant, which can sometimes restore a high level of auditory function even when natural hearing is totally lost However, the amount of destruction to the cochlear nerve caused by the typical NF2 schwannoma often precludes the use of such an implant In these cases, an auditory brainstem implant ABI can restore a primitive level of hearing, which, when supplemented by lip reading, can restore a functional understanding of spoken language


The clinical spectrum of the condition is broad In other words, people with NF II may develop a wide range of distinct problems

  1. Acoustic nerve: 90% of the patients show bilateral acoustic schwannomas on magnetic resonance imaging MRI
  2. Other cranial nerves and meninges: About 50% of patients develop tumours in other cranial nerves or meningiomas
  3. Spinal cord: About 50% of the patients develop spinal lesions Only 40% of the spinal lesions are symptomatic The spinal tumours in NF II are separated in two groups Intramedullary lesions are located within the spinal tissue and usually belong to the so-called spinal astrocytomas or ependymomas The extramedullary lesions are located within the small space between the surface of the spinal cord and the bony wall of the spinal canal These tumours belong to the schwannomas and meningiomas
  4. Skin: If children show neurofibromas, a diagnostic procedure should be performed to decide which form of neurofibromatosis causes the alterations
  5. Eyes: Studies on patients with NF II show that more than 90% of the affected persons suffer eye lesions The most common alteration in NF II is the juvenile subcapsular cataract opacity of the lens in young people

"Presenting symptoms" initial concern that brings a patient to a doctor of a lesion of the nervus vestibulocochlearis due to a tumour in the region of the cerebello-pontine angle are the following: hearing loss 98%, tinnitus 70%, dysequilibrium 67%, headache 32%, facial numbness and weakness 29% and 10% respectively

"Clinical signs" alterations that are not regarded by the patient and that can be detected by the doctor in a clinical examination of the lesion in discussion are: abnormal corneal reflex 33%, nystagmus 26%, facial hypesthesia 26%

Evaluation study of the patient with technical methods shows the enlargement of the porus acousticus internus in the CT scan, enhancing tumours in the region of the cerebello-pontine angle in gadolinium-enhanced MRI scans, hearing loss in audiometric studies and perhaps pathological findings in electronystagmography Some times there are elevated levels of protein in liquor study

In NF II, acoustic neuromas usually affect young people, whereas in sporadic forms of acoustic neuromas, the appearance of the tumour is limited to the elderly

There are two forms of the NF II:12

  • The Wishart-Phenotype is characterized by multiple cerebral and spinal lesions in patients younger than 20 years and with rapid progression of the tumours
  • Patients that develop single central tumours with slow progression after age of 20 are thought to have the Feiling-Gardner-Phenotype

See alsoedit

  • List of neurofibromatosis charities


  1. ^ Striedinger K, VandenBerg SR, Baia GS, McDermott MW, Gutmann DH, Lal A November 2008 "The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP" Neoplasia 10 11: 1204–12 PMC 2570596  PMID 18953429 
  2. ^ Rouleau, GA; Merel, P; Lutchman, M; Sanson, M; Zucman, J; Marineau, C; Hoang-Xuan, K; Demczuk, S; Desmaze, C; Plougastel, B 10 June 1993 "Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2" Nature 363 6429: 515–21 PMID 8379998 doi:101038/363515a0 
  3. ^ Evans DG 2009 "Neurofibromatosis type 2 NF2: a clinical and molecular review" Orphanet J Rare Dis 4: 16 PMC 2708144  PMID 19545378 doi:101186/1750-1172-4-16 
  4. ^ a b Stamenkovic, I; Yu, Q 2010 "Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival" Current protein & peptide science 11 6: 471–84 PMC 2946555  PMID 20491622 doi:102174/138920310791824011 
  5. ^ Christopher Gillberg 16 October 2003 Clinical Child Neuropsychiatry Cambridge University Press pp 231– ISBN 978-0-521-54335-4 Retrieved 20 December 2010 
  6. ^ "Are there any prenatal tests for the neurofibromatoses"
  7. ^ Ferner, Rosalie E, Susan M Huson, and D Gareth R Evans Neurofibromatoses in clinical practice Springer, 2011
  8. ^ "Neurofibromatosis Type 2: eMedicine Radiology" Retrieved 2010-12-20 
  9. ^ Jean Régis; Pierre-Hugues Roche 2008 Modern Management of Acoustic Neuroma Karger Publishers pp 191– ISBN 978-3-8055-8370-1 Retrieved 20 December 2010 
  10. ^ http://contentnejmorg/cgi/content/full/NEJMoa0902579v1
  11. ^ Mautner VF, Nguyen R, Kutta H, et al January 2010 "Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2" Neuro-oncology 12 1: 14–8 PMC 2940556  PMID 20150363 doi:101093/neuonc/nop010 
  12. ^ Walter J, Kuhn SA, Brodhun M, Reichart R, Kalff R June 2009 "Pulmonary meningioma and neurinoma associated with multiple CNS tumours in a patient with neurofibromatosis type 2" Clin Neurol Neurosurg 111 5: 454–9 PMID 19249154 doi:101016/jclineuro200811018 

Further readingedit

  • Evans, D Gareth 1993 "Neurofibromatosis 2" GeneReviews® University of Washington, Seattle Retrieved 30 May 2017 

neurofibromatosis type ii, neurofibromatosis type ii (nf2), neurofibromatosis type ii (nfii), neurofibromatosis type ii affect an individual, neurofibromatosis type ii baby, neurofibromatosis type ii mri, neurofibromatosis type ii symptoms, neurofibromatosis type iii

Neurofibromatosis type II Information about

Neurofibromatosis type II

  • user icon

    Neurofibromatosis type II beatiful post thanks!


Neurofibromatosis type II
Neurofibromatosis type II
Neurofibromatosis type II viewing the topic.
Neurofibromatosis type II what, Neurofibromatosis type II who, Neurofibromatosis type II explanation

There are excerpts from wikipedia on this article and video

Random Posts

B♭ (musical note)

B♭ (musical note)

B♭ B-flat; also called si bémol is the eleventh step of the Western chromatic scale starting from C ...
Fourth dimension in art

Fourth dimension in art

New possibilities opened up by the concept of four-dimensional space and difficulties involved in tr...
Holt Renfrew

Holt Renfrew

Holt, Renfrew & Co, Limited, commonly known as Holt Renfrew or Holt's,1 is a chain of high-end C...
Later Silla

Later Silla

Later Silla 668–935, Hangul: 후신라; Hanja: 後新羅; RR: Hushila, Korean pronunciation: ...